Johnson & Johnson has issued a Topamax recall after receiving complaints about an unusual odor linked to a byproduct from a chemical used in treating wood. Sources believe the contamination may have occurred as a result of the way medication is shipped and stored.
Topamax has recently come under fire after the FDA issued warnings of an increased risk of cleft lips and cleft palates in infants of mothers who take Topamax (topiramate) during pregnancy.
The FDA has given the Topamax a pregnancy risk rating of D, indicating positive evidence of human fetal risk and birth defects.
Topamax has also been linked to eye disorders such as blurred vision, acute myopia and secondary angle closure glaucoma.